Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Skilled Nursing Facilities | 9 | 2021 | 1098 | 1.00 | Why? |
| Nursing Homes | 6 | 2022 | 4155 | 0.53 | Why? |
| Medicaid | 1 | 2019 | 492 | 0.53 | Why? |
| Medicare | 3 | 2018 | 1048 | 0.53 | Why? |
| Surgical Wound Infection | 1 | 2019 | 501 | 0.51 | Why? |
| Insurance, Health | 1 | 2019 | 634 | 0.51 | Why? |
| Insurance, Health, Reimbursement | 1 | 2015 | 205 | 0.50 | Why? |
| Cross Infection | 8 | 2020 | 8675 | 0.49 | Why? |
| Clostridium Infections | 1 | 2020 | 595 | 0.47 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 4 | 2019 | 711 | 0.46 | Why? |
| Drug Prescriptions | 1 | 2020 | 1062 | 0.43 | Why? |
| Catheter-Related Infections | 1 | 2015 | 381 | 0.43 | Why? |
| Prosthesis-Related Infections | 1 | 2015 | 302 | 0.43 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2015 | 363 | 0.39 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2015 | 403 | 0.38 | Why? |
| Staphylococcal Infections | 4 | 2019 | 1099 | 0.37 | Why? |
| Cesarean Section | 1 | 2019 | 2089 | 0.36 | Why? |
| Assisted Living Facilities | 2 | 2020 | 264 | 0.32 | Why? |
| Anti-Bacterial Agents | 6 | 2020 | 10083 | 0.31 | Why? |
| Patient Readmission | 1 | 2015 | 1543 | 0.30 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.30 | Why? |
| Staphylococcus aureus | 3 | 2019 | 844 | 0.28 | Why? |
| Methicillin | 3 | 2019 | 73 | 0.26 | Why? |
| Housing for the Elderly | 2 | 2020 | 59 | 0.26 | Why? |
| United States | 20 | 2021 | 46150 | 0.25 | Why? |
| Disease Outbreaks | 13 | 2021 | 27595 | 0.24 | Why? |
| Clinical Laboratory Techniques | 6 | 2020 | 23402 | 0.23 | Why? |
| Vancomycin | 2 | 2020 | 328 | 0.21 | Why? |
| Dialysis | 1 | 2020 | 45 | 0.21 | Why? |
| Ecological and Environmental Phenomena | 1 | 2020 | 25 | 0.21 | Why? |
| Washington | 6 | 2020 | 1722 | 0.21 | Why? |
| Metronidazole | 1 | 2020 | 59 | 0.20 | Why? |
| Mupirocin | 1 | 2019 | 22 | 0.20 | Why? |
| Asymptomatic Diseases | 3 | 2020 | 3444 | 0.19 | Why? |
| Reverse Transcription | 1 | 2022 | 673 | 0.18 | Why? |
| Fluoroquinolones | 1 | 2020 | 235 | 0.18 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.18 | Why? |
| Cephalosporins | 1 | 2020 | 250 | 0.17 | Why? |
| Chlorhexidine | 1 | 2019 | 176 | 0.17 | Why? |
| Hospitals, Veterans | 1 | 2019 | 229 | 0.16 | Why? |
| Sepsis | 3 | 2018 | 3517 | 0.16 | Why? |
| Private Sector | 1 | 2019 | 262 | 0.16 | Why? |
| Interrupted Time Series Analysis | 1 | 2020 | 868 | 0.15 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.14 | Why? |
| Residential Facilities | 1 | 2020 | 443 | 0.14 | Why? |
| Enterobacteriaceae Infections | 2 | 2017 | 529 | 0.14 | Why? |
| Severe Acute Respiratory Syndrome | 4 | 2005 | 12361 | 0.13 | Why? |
| Coronavirus Infections | 13 | 2020 | 253789 | 0.13 | Why? |
| United States Department of Veterans Affairs | 1 | 2017 | 553 | 0.13 | Why? |
| Aged | 24 | 2021 | 215776 | 0.13 | Why? |
| Central Venous Catheters | 1 | 2015 | 188 | 0.12 | Why? |
| Drug Utilization | 1 | 2018 | 619 | 0.12 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.12 | Why? |
| Anti-Infective Agents, Local | 1 | 2019 | 520 | 0.12 | Why? |
| California | 1 | 2019 | 2047 | 0.12 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2017 | 398 | 0.12 | Why? |
| Shock, Septic | 2 | 2018 | 1313 | 0.11 | Why? |
| Pneumonia, Viral | 10 | 2020 | 243684 | 0.11 | Why? |
| Hospitals | 3 | 2020 | 11793 | 0.11 | Why? |
| Humans | 38 | 2022 | 930598 | 0.10 | Why? |
| Aged, 80 and over | 14 | 2021 | 88759 | 0.10 | Why? |
| Retrospective Studies | 11 | 2021 | 105322 | 0.09 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.09 | Why? |
| Length of Stay | 2 | 2018 | 11042 | 0.09 | Why? |
| Disease Transmission, Infectious | 3 | 2020 | 9044 | 0.09 | Why? |
| Female | 23 | 2021 | 380317 | 0.09 | Why? |
| Bacteremia | 1 | 2019 | 1372 | 0.09 | Why? |
| Multivariate Analysis | 1 | 2019 | 5440 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.09 | Why? |
| Electronic Health Records | 2 | 2019 | 3492 | 0.09 | Why? |
| Infection Control | 7 | 2020 | 23131 | 0.08 | Why? |
| Male | 23 | 2021 | 367725 | 0.08 | Why? |
| Hospitalization | 5 | 2020 | 54280 | 0.07 | Why? |
| Disinfection | 1 | 2019 | 2912 | 0.07 | Why? |
| Epidemiologic Factors | 1 | 2004 | 11 | 0.07 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 2 | 2016 | 8843 | 0.07 | Why? |
| Vancomycin Resistance | 1 | 2004 | 55 | 0.07 | Why? |
| Logistic Models | 1 | 2019 | 9089 | 0.07 | Why? |
| Long-Term Care | 3 | 2020 | 2047 | 0.07 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.07 | Why? |
| Health Facilities | 2 | 2017 | 1230 | 0.06 | Why? |
| Health Personnel | 5 | 2021 | 29646 | 0.06 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.06 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.06 | Why? |
| Adult | 12 | 2020 | 244371 | 0.06 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.06 | Why? |
| Middle Aged | 15 | 2021 | 270681 | 0.06 | Why? |
| Population Surveillance | 1 | 2019 | 4967 | 0.06 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2022 | 13720 | 0.06 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.05 | Why? |
| Emergency Service, Hospital | 1 | 2004 | 14232 | 0.05 | Why? |
| Polyenes | 1 | 2018 | 16 | 0.05 | Why? |
| Survival | 1 | 2018 | 53 | 0.05 | Why? |
| Connecticut | 1 | 2021 | 547 | 0.05 | Why? |
| Maryland | 1 | 2020 | 436 | 0.05 | Why? |
| Minnesota | 1 | 2020 | 509 | 0.05 | Why? |
| Hospital Charges | 1 | 2018 | 56 | 0.05 | Why? |
| Insurance Claim Reporting | 1 | 2017 | 22 | 0.05 | Why? |
| Adolescent | 5 | 2020 | 86841 | 0.04 | Why? |
| Tertiary Care Centers | 1 | 2016 | 8248 | 0.04 | Why? |
| Medical Records | 1 | 2021 | 513 | 0.04 | Why? |
| Echinocandins | 1 | 2018 | 139 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Azoles | 1 | 2018 | 185 | 0.04 | Why? |
| Pregnancy | 1 | 2019 | 23879 | 0.04 | Why? |
| Hygiene | 2 | 2019 | 987 | 0.04 | Why? |
| Michigan | 1 | 2020 | 988 | 0.04 | Why? |
| Medical Audit | 1 | 2017 | 218 | 0.04 | Why? |
| Carrier State | 2 | 2019 | 2100 | 0.04 | Why? |
| Clinical Coding | 1 | 2017 | 172 | 0.04 | Why? |
| False Positive Reactions | 1 | 2021 | 1338 | 0.04 | Why? |
| Saudi Arabia | 2 | 2016 | 4423 | 0.04 | Why? |
| Cluster Analysis | 1 | 2004 | 3001 | 0.04 | Why? |
| Administration, Intranasal | 1 | 2019 | 1132 | 0.03 | Why? |
| False Negative Reactions | 1 | 2021 | 1785 | 0.03 | Why? |
| Acinetobacter Infections | 1 | 2017 | 273 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Immunization Schedule | 1 | 2021 | 1305 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.03 | Why? |
| Pseudomonas Infections | 1 | 2017 | 425 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Incidence | 3 | 2019 | 25622 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Hospital Mortality | 3 | 2019 | 22087 | 0.03 | Why? |
| Decision Making | 1 | 2004 | 3132 | 0.02 | Why? |
| Child | 1 | 2019 | 70012 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2004 | 7220 | 0.02 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2017 | 1115 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2019 | 1476 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.02 | Why? |
| Propensity Score | 1 | 2017 | 2690 | 0.02 | Why? |
| Genome, Viral | 2 | 2020 | 13157 | 0.02 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Communication | 1 | 2004 | 5206 | 0.02 | Why? |
| Chronic Disease | 1 | 2020 | 5139 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Databases, Factual | 1 | 2019 | 6248 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Respiratory Tract Infections | 1 | 2004 | 6817 | 0.02 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.01 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.01 | Why? |
| SARS Virus | 1 | 2005 | 13021 | 0.01 | Why? |
| Seroepidemiologic Studies | 1 | 2016 | 10017 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.01 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Public Health | 1 | 2004 | 16359 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Prospective Studies | 1 | 2021 | 43301 | 0.01 | Why? |
| Microbial Sensitivity Tests | 1 | 2004 | 2886 | 0.01 | Why? |
| Drug Resistance, Bacterial | 1 | 2004 | 1414 | 0.01 | Why? |
| Disaster Planning | 1 | 2004 | 1680 | 0.01 | Why? |
| Patient Isolation | 1 | 2004 | 3182 | 0.01 | Why? |
| Communicable Diseases, Emerging | 1 | 2005 | 2523 | 0.01 | Why? |
Jernigan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(166)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(249)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_